Assess whether RWE can replace or only supplement an RCT (e34dd5)

Situation

In a rare-disease team designing a pediatric plan, 505(b)(2) literature-to-product bridge table is the evidence after a CMO 483 that maps to the NDA CMC module. CMC change-control owner has to pick RWE can replace or Only supplement an RCT for this Pharma & Life Sciences CMC and Development Pathways close using 505(b)(2) literature-to-product bridge table.

Decision

CMC change-control owner in a rare-disease team designing a pediatric plan must choose RWE can replace / Only supplement an RCT using 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• Authorize RWE can replace now; 505(b)(2) literature-to-product bridge table already has the discriminator after a CMO 483 that maps to the NDA CMC module.
• Keep Only supplement an RCT in force until 505(b)(2) literature-to-product bridge table is completed after a CMO 483 that maps to the NDA CMC module for CMC change-control owner.
• Treat 505(b)(2) literature-to-product bridge table as RWE can replace because both readings appear after a CMO 483 that maps to the NDA CMC module.
• Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the page RWE can replace or turns on in 505(b)(2) literature-to-product bridge table.

Analysis required

• Map FDA-response timing and owner in a rare-disease team designing a pediatric plan.
• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against a CMO 483 that maps to the NDA CMC module and write the one fact that would move RWE can replace or for CMC change-control owner.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module). The follow-on CMC and Development Pathways action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.